Accord Aims At Addiction With Buprenorphine Implant Deal
Agreement Sees Firm Distribute Sixmo For Molteni Farmaceutici In Europe
Accord is kicking off plans to launch a number of addiction treatments by partnering with Molteni Farmaceutici on distributing its Sixmo six-month buprenorphine implant in Europe.
You may also be interested in...
Molteni Farmaceutici/Titan’s Sixmo, the first six-month buprenorphine implant just approved for EU marketing, could be a valued option for a sizeable number of patients.
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.